How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Positive Long-Term HELIOS-B Results for AMVUTTRA

• Alnylam Pharmaceuticals recently presented positive long-term data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at the European Society of Cardiology Congress 2025, showing durable reductions in all-cause mortality and cardiovascular events for adults with ATTR-CM across up to 48 months of treatment.
• The study also highlighted sustained improvements in quality of life and days lost to death or hospitalization, with a consistent long-term safety profile supporting vutrisiran’s continued use in diverse international patient populations.
• We'll explore how these latest HELIOS-B trial results further strengthen Alnylam's RNAi leadership and rare disease innovation thesis.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Alnylam Pharmaceuticals Investment Narrative Recap

To own shares in Alnylam Pharmaceuticals, you need conviction in the company’s RNAi leadership and the sustained expansion of its transthyretin amyloidosis franchise, especially with AMVUTTRA. The newly presented HELIOS-B results may support Alnylam’s near-term global growth plans but do not fundamentally change the main short-term catalyst, which remains the pace and breadth of international AMVUTTRA uptake. The biggest risk remains pricing pressure and reimbursement hurdles, which could affect revenue per prescription and margins despite clinical progress.

Of the recent company announcements, the June 2025 European Commission marketing authorization for AMVUTTRA in wild-type or hereditary ATTR-CM aligns closely with the HELIOS-B results, reinforcing its first-in-class approval and expanding Alnylam’s addressable market in Europe. This regulatory validation could accelerate access and reinforce payer negotiations in new jurisdictions, supporting broader revenue growth and complementing ongoing clinical momentum.

However, even with stronger clinical evidence and new approvals, investors should be aware that persistent concerns over pricing headwinds and payer pushback remain...

Read the full narrative on Alnylam Pharmaceuticals (it's free!)

Alnylam Pharmaceuticals' outlook anticipates $7.0 billion in revenue and $1.9 billion in earnings by 2028. This implies a 41.8% annual revenue growth rate and a $2.2 billion increase in earnings from the current level of -$319.1 million.

Uncover how Alnylam Pharmaceuticals' forecasts yield a $426.26 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates range from US$225.68 to US$583 per share, showing a wide spectrum of expectations. Many expect robust revenue growth opportunities, yet risks to sustained profitability and margin expansion continue to shape the outlook for Alnylam’s future earnings trajectory.

Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth as much as 29% more than the current price!

Build Your Own Alnylam Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com